Ongoing clinical studies of imetelstat consist of IMerge, a Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS) and IMbark
, a Phase 2 trial in Intermediate-2 or High-risk myelofibrosis.
Abstract Title: Favorable Overall Survival of Imetelstat-Treated Relapsed/Refractory Myelofibrosis Patients Compared with Closely Matched Real World Data: This poster presentation provided a new analysis of overall survival in relapsed/refractory MF patients treated with imetelstat 9.4 mg/kg in the IMbark
Phase 2 clinical trial, compared to OS calculated from real world data collected at the Moffitt Cancer Center for patients who had discontinued treatment from ruxolitinib, a JAK inhibitor, and who were subsequently treated with best available therapy.
And to Ship myself upon the first Vessel or Ship that the Committee of the said Company shall Order me to imbark
in, that shall go, or is bound for HUDSON'S-BAY; where I oblige myself to stay according to the aforesaid limited Time, and to do, and perform such Labour and Work, and obey such Commands as the Governor in HUDSON'S BAY, or chief Factor there, shall impose upon me.
Why, moreover, had he relinquished "a calme and pleasing solitarynes fed with cheerful and confident thoughts, to imbark
in a troubl'd sea of noises and hoars disputes" (1959, 1:821)?
Geron believes the clinical results from IMbark
provide insights into the potential future development of imetelstat for an underserved relapsed and refractory myelofibrosis patient population and that the combined data of 38 patients from the initial and expansion cohorts for the target patient population from the Phase 2 portion of IMerge support further development of imetelstat.
The stock saw big gains in mid-March (after earnings) when the company said that primary analysis for its IMbark
will start at the end of the second quarter of 2018, with a Continuation Decision by the end of the third quarter of 2018.
Imetelstat's prospects are still dim, but in short term, Scarlett is working it." WHAT'S NOTABLE: On Thursday, Seeking Alpha contributor "Alpha Exposure" said the recent update from Geron "was definitely negative," and confirmed their view of imetelstat's "likely failure." The contributor, who is short the shares, believes "IMbark
may have a healthier patient population which explains the longer than expected overall survival" and Geron provided proof that the treatment has no impact on survival by reporting no difference in median survival in either dosing arm.